T1	p 100 135	patients with early breast cancer :
T2	p 314 347	patients with early breast cancer
T3	i 36 39	FEC
T4	i 54 75	growth factor support
T5	i 243 253	epirubicin
T6	i 474 522	fluorouracil/epirubicin/cyclophosphamide ( FEC )
T7	i 618 629	FEC ( 100 )
T8	i 709 734	dose-dense FEC regimens .
T9	i 777 787	FEC ( 75 )
T10	i 791 801	FEC ( 90 )
T11	i 886 899	pegfilgrastim
T12	i 1179 1189	FEC ( 75 )
T13	i 1242 1252	FEC ( 90 )
T14	i 1411 1425	( FEC ( 90 ) )
T15	i 1524 1534	FEC ( 90 )
T16	i 1757 1771	( FEC ( 90 ) )
T17	i 1867 1875	FEC ( 75
T18	i 1882 1892	FEC ( 90 )
T19	o 1003 1070	proportion of subjects receiving > or =85 % relative dose intensity
T20	o 1317 1331	adverse events
T21	o 1336 1365	personal/logistical reasons .
T22	o 1439 1486	diarrhoea . Grade 3-4 haematological toxicities
T23	o 1569 1588	febrile neutropenia
T24	o 1657 1700	liver enzymes and gastrointestinal events ;
T25	o 1784 1839	serious adverse events ( vomiting and throat oedema ) .
T26	o 1989 2009	Grade 3-4 toxicity .